Literature DB >> 32745179

Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.

Sebastian Ochoa1, Li Ding1, Samantha Kreuzburg1, Jennifer Treat2, Steven M Holland1, Christa S Zerbe1.   

Abstract

Patients with autoantibodies to interferon-γ (IFN-γ) may develop severe nontuberculous mycobacterial infections. We describe the novel use of daratumumab in a patient with autoantibodies to IFN-γ who had progressive infection, resulting in clinical and radiographic improvement. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  autoantibodies; daratumumab; disseminated; interferon gamma; mycobacteria

Mesh：

Substances：

Year:  2021        PMID： 32745179      PMCID： PMC8204786          DOI： 10.1093/cid/ciaa1086

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

2.  Determination of human anticytokine autoantibody profiles using a particle-based approach.

Authors:  Li Ding; Allen Mo; Kamonwan Jutivorakool; Minjal Pancholi; Steven M Holland; Sarah K Browne
Journal:  J Clin Immunol       Date:  2011-12-06       Impact factor: 8.317

3.  Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.

Authors:  Claudia I Chapuy; Richard M Kaufman; Edwin P Alyea; Jean M Connors
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

4.  Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States.

Authors:  Gloria H Hong; Ana M Ortega-Villa; Sally Hunsberger; Ploenchan Chetchotisakd; Siriluck Anunnatsiri; Piroon Mootsikapun; Lindsey B Rosen; Christa S Zerbe; Steven M Holland
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

5.  Monoclonal antibody utilization characteristics in patients with multiple myeloma.

Authors:  Sikander Ailawadhi; Taimur Sher; Abdel-Ghani Azzouqa; Zahara Meghji; Tania Jain; Prachi Jani; Salman Ahmed; Nancy Diehl; Vivek Roy; Vishal Shah; David Hodge; Meghna Ailawadhi; Victoria R Alegria; Aneel Paulus; Asher Chanan-Khan; Rafael Fonseca
Journal:  Anticancer Drugs       Date:  2019-09       Impact factor: 2.248

6.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

7.  Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation.

Authors:  Catharina Schuetz; Manfred Hoenig; Despina Moshous; Christof Weinstock; Martin Castelle; Matthieu Bendavid; Kristin Shimano; Vanessa Tolbert; Ansgar S Schulz; Christopher C Dvorak
Journal:  Blood Adv       Date:  2018-10-09

Review 8.  Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Authors:  Ajay K Nooka; Charise Gleason; Marva Ollivierre Sargeant; Michelle Walker; Melanie Watson; Elyse Hall Panjic; Sagar Lonial
Journal:  J Oncol Pract       Date:  2018-07       Impact factor: 3.840
  9 in total
  7 in total

Review 1.  Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity.

Authors:  Aristine Cheng; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2022-01       Impact factor: 14.290

Review 2.  Minireview: Insights into anti-interferon-γ autoantibodies.

Authors:  Kriangkrai Chawansuntati; Kritsadee Rattanathammethee; Jiraprapa Wipasa
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-11

Review 3.  Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection.

Authors:  Long-Fang Chen; Cheng-De Yang; Xiao-Bing Cheng
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

4.  Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.

Authors:  Donald C Vinh; Laurent Abel; Paul Bastard; Matthew P Cheng; Antonio Condino-Neto; Peter K Gregersen; Filomeen Haerynck; Maria-Pia Cicalese; David Hagin; Pere Soler-Palacín; Anna M Planas; Aurora Pujol; Luigi D Notarangelo; Qian Zhang; Helen C Su; Jean-Laurent Casanova; Isabelle Meyts
Journal:  J Clin Immunol       Date:  2021-06-08       Impact factor: 8.542

5.  R-CHOP Chemotherapy for Disseminated Mycobacterium avium Complex Disease due to Anti-Interferon-Gamma Autoantibodies: A Case Report.

Authors:  Shunsuke Uno; Eisuke Uehara; Toshiki Kimura; Takuro Sakagami; Ho Namkoong; Sho Uchida; Yoshifumi Uwamino; Naoki Hasegawa
Journal:  Open Forum Infect Dis       Date:  2021-04-10       Impact factor: 3.835

6.  Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies.

Authors:  Joseph M Rocco; Lindsey B Rosen; Gloria H Hong; Jennifer Treat; Samantha Kreuzburg; Steven M Holland; Christa S Zerbe
Journal:  J Transl Autoimmun       Date:  2021-05-04

7.  Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies.

Authors:  Elizabeth M King; Victoria K Weaver; Mary H Kestler
Journal:  Open Forum Infect Dis       Date:  2021-06-23       Impact factor: 3.835
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.